The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Next Oncology
A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors.
 
Alexander Starodub
Consulting or Advisory Role - Bayer; Sandoz
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Raghad Karim
No Relationships to Disclose
 
Curtis Ruegg
Employment - Amphivena Therapeutics Inc; Parvus Therapeutics
Leadership - Amphivena Therapeutics, Inc.; Parvus Therapeutics
Stock and Other Ownership Interests - Amphivena Therapeutics Inc.; Parvus Therapeutics
 
Victoria Smith
Employment - Amphivena Therapeutics
Leadership - Amphivena Therapeutics
Stock and Other Ownership Interests - Amphivena Therapeutics
Patents, Royalties, Other Intellectual Property - Amphivena Therapeutics
 
Patrick Youngwhan Chun
Employment - Amphivena Therapeutics; Amphivena Therapeutics; Gilead Sciences; Merck Sharp & Dohme; Zentalis
Stock and Other Ownership Interests - Amphivena Therapeutics; Gilead Sciences; Zentalis
Travel, Accommodations, Expenses - Gilead Sciences; Zentalis